Knowledge Distillery

The objective of this simulation agent based modeling study was to estimate population health outcomes with delayed second dose versus standard…

The objective of this population based cohort study was to assess rates of cardiovascular and haemostatic events in the first 28 days after…

Pregnant women are at increased risk of morbidity and mortality from COVID-19 but have been excluded from the phase 3 COVID-19 vaccine trials. Data on…

Cerebral venous sinus thrombosis (CVST) with thrombocytopenia, a rare and serious condition, has been described in Europe following receipt of the…

The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase 3…

Two mRNA vaccines, BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), received Emergency Use Authorization from the US Food and Drug Administration.…

The Ad26.COV2.S vaccine has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially…

Whilst SARS-CoV-2 vaccines are very safe, in this brief communication the authors report four cases of the bifacial weakness with paraesthesias…

As of April 22, 2021, around 1.5 million individuals in 3 districts of Kerala, India had been vaccinated with COVID-19 vaccines.

Vaccine induced immune mediated thrombocytopenia or VITT, is a recent and rare phenomenon of thrombosis with thrombocytopenia, frequently including…

The B.1.617.2 (delta) variant of the SARS-CoV-2, the virus that causes Covid-19, has contributed to a surge in cases in India and has now been…

Because of concerns about thrombotic events after vaccination with ChAdOx1 nCoV-19 (Oxford–AstraZeneca), several European countries have recommended…